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The mitotic checkpoint prevents mitotic exit until all chromosomes are attached to spindle 
microtubules. Aurora B kinase indirectly invokes this checkpoint by destabilizing incorrect 
attachments; however, a more direct role remains controversial. In contrast, activity of the 
kinase mps1 is indispensible for the mitotic checkpoint. Here we show that Aurora B and Hec1 
are needed for efficient mps1 recruitment to unattached kinetochores, allowing rapid mps1 
activation at the onset of mitosis. Live monitoring of cyclin B degradation reveals that this 
is essential to establish the mitotic checkpoint quickly at the start of mitosis. Delayed mps1 
activation and checkpoint establishment upon Aurora B inhibition or Hec1 depletion are rescued 
by tethering mps1 to kinetochores, demonstrating that mps1 recruitment is the primary role of 
Aurora B and Hec1 in mitotic checkpoint signalling. These data demonstrate a direct role for 
Aurora B in initiating the mitotic checkpoint rapidly at the onset of mitosis. 
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T
he  anaphase-promoting  complex/cyclosome  (APC/C)  is 
the ubiquitin ligase responsible for degrading cyclin B and 
securin to allow sister chromatid separation and mitotic exit 
(reviewed in ref. 1). The APC/C remains inhibited until all chromo-
somes are attached to microtubules via their kinetochores, because 
unattached kinetochores catalyse production of an APC/C inhibi-
tor termed the mitotic checkpoint complex ((refs 2–5) and reviewed 
in ref. 6). A key step in this catalysis is the conformational activa-
tion of the checkpoint protein Mad2 to a form known as C-Mad2 
(reviewed in ref. 7), which is able to bind to the APC/C coactivator 
protein Cdc20 and ultimately cause efficient APC/C inhibition. The 
initial recruitment of Mad2 to kinetochores and its subsequent con-
version to C-Mad2 rely on the kinase Mps1 (refs 8–11).
Chromosomes with erroneous kinetochore–microtubule attach-
ments can indirectly engage the mitotic checkpoint by virtue of unat-
tached intermediates that are formed during the error-correction   
process12,13. Error correction is mediated by the chromosomal pas-
senger complex that contains Aurora B as its executioner kinase 
(reviewed in ref. 14). Aurora B is thought to cause release of faulty 
attachments via phosphorylation of Hec1 and other components of 
the KMN network that form the core microtubule-binding site at 
the  kinetochore,  thereby  reducing  its  microtubule-binding  affin-
ity15–18. It is currently unknown whether Aurora B has more direct 
roles in the mitotic checkpoint, as studies using different experi-
mental systems reached conflicting conclusions13,19–23.
We show here that Aurora B activity is critical to establish the 
checkpoint  quickly  following  mitotic  entry  in  mammalian  cells. 
Aurora B enhances the recruitment of Mps1 to unattached kineto-
chores, which is needed to achieve rapid Mps1 activation at the onset 
of mitosis. This is the primary direct role for Aurora B in the mitotic 
checkpoint as recovering Mps1 recruitment to kinetochores rescues 
all checkpoint phenotypes associated with Aurora B inhibition in 
nocodazole-arrested cells. Aurora B therefore directly impacts on 
mitotic checkpoint function by ensuring timely Mps1 activation as 
soon as cells enter mitosis.
Results
Aurora B inhibition delays Mps1 activation during mitosis. We, 
along with others, have recently implicated Aurora B as a factor 
involved  in  kinetochore  binding  of  inactive  Mps1  (refs  24,  25).   
To examine whether this function of Aurora B could impact on the 
mitotic checkpoint, localization and activity of Mps1 were monitored 
following  mitotic  entry  in  the  presence  of  Aurora  B  inhibitors.   
To exclude the indirect effects of Aurora B inhibition on the mitotic 
checkpoint,  which  arise  from  its  ability  to  affect  kinetochore–
microtubule interactions, these and all further experiments were 
performed  in  the  presence  of  the  microtubule-depolymerizing 
drug nocodazole (unless stated otherwise). Mps1 strongly localized 
to kinetochores during prophase and early prometaphase26 (‘early 
prometaphase’ cells had lightly condensed chromosomes that were 
scattered in the cytoplasm in contrast to ‘late prometaphase’ cells that 
had a highly condensed chromosome mass typical of nocodazole-
arrested cells; Fig. 1a,b). Aurora B inhibition using the small molecules 
Hesperadin or ZM447439 (hereafter referred to as Hesp or ZM in all 
figures)22,23 reduced Mps1 kinetochore binding throughout mitosis 
(Fig. 1a,b). To examine if this reduction in kinetochore binding 
affected Mps1 activity, we assayed Mad2 localization to kinetochores, 
which requires kinase activity of Mps1 (refs 8–11, 25 and 27). This 
therefore enabled quantification of Mps1 activity within single cells. 
As  expected26,  Mad2  recruitment  was  initiated  in  prophase  and 
peaked in the early prometaphase cells (Fig. 1a,b). In contrast to the 
reduction in Mps1 kinetochore binding throughout mitosis, Mad2 
levels were only significantly affected by Aurora B inhibition during 
the early stages (Fig. 1a,b). Similar effects on localization of Mps1 and 
Mad2 were observed after short interfering RNA (siRNA)-mediated   
knockdown of Aurora B (Supplementary Fig. S1). To confirm that 
Mps1  activity  at  kinetochores  was  directly  affected  by  Aurora 
B  inhibition,  we  used  an  antibody  against  the  activation  loop 
phosphorylation site in Mps1 (pT676). Phosphorylation of this site 
is needed for full Mps1 activity and has been used previously as a 
marker for Mps1 activation28. Figure 1c shows that kinetochore-
localized  pT676  was  reduced  during  the  early  prometaphase 
following Mps1 knockdown or inhibition, validating this antibody 
as  a  direct  measure  for  Mps1  activity  at  kinetochores  (note 
background centrosomic staining with this antibody is nonspecific 
and  does  not  change  upon  Mps1  knockdown  or  inhibition). 
As  expected,  Aurora  B  inhibition  led  to  a  direct  reduction  in 
kinetochore-localized Mps1 activity during the early prometaphase 
(Fig. 1c).
To  further  ensure  that  Mad2  loss  from  kinetochores  was 
a  direct  consequence  of  reduced  Mps1  activity,  we  examined 
whether Mad2 levels could be recovered in Aurora B-inhibited 
cells when Mps1 activity at kinetochores was restored. We have 
previously  used  a  Mis12–Mps1  fusion  protein  to  constitutively 
tether  Mps1  to  kinetochores24.  For  these  purposes,  the  kineto-
chore-targeting domain (amino acids 1–200; refs 27, 29, AS and 
GJPLK, unpublished data) was removed to prevent any Aurora B-
dependent inputs on Mis12–Mps1. Doxycycline-inducible expres-
sion of Mis12–Mps1∆200 showed that the fusion protein localized 
constitutively  to  kinetochores  independently  of  Aurora  B  and 
rescued mitotic checkpoint defects caused by depletion of endog-
enous Mps1 (GJPLK, unpublished results). Importantly, induced 
expression of Mis12–Mps1∆200 before mitotic entry prevented the 
reduction in Mad2 kinetochore binding seen following Aurora B 
inhibition (Fig. 1d for early prometaphase cells and Supplemen-
tary Fig. S2 for all mitotic stages), confirming that the Aurora B-
mediated effects on Mad2 are a consequence of impaired Mps1 
activity  at  kinetochores.  Furthermore,  artificial  recruitment  of 
Mps1 to kinetochores before mitosis by inducible expression of 
Mis12–Mps1∆200  caused  Mad2  accumulation  at  kinetochores  of 
G2-phase cells (Supplementary Fig. S3). Although we cannot for-
mally exclude that the rescue by Mis12–Mps1∆200 is mediated in 
part by cytoplasmic functions of Mps1, our observations that high 
cytoplasmic  levels  of  non-kinetochore-bound  Mps1∆200  did  not 
rescue Mad2 recruitment or checkpoint activity (Supplementary 
Figs S3 and S4) strongly suggest that these effects are specifically 
due to kinetochore-localized Mps1 activity. Collectively, these data 
demonstrate that Aurora B promotes Mad2 kinetochore binding in 
early mitosis by localizing Mps1 activity to kinetochores.
Aurora B inhibition reduced Mps1 localization to unattached 
kinetochores throughout mitosis, but it only significantly reduced 
Mps1 activity at kinetochores during the early stages (Fig. 1a,b). 
Mps1 is thought to auto-activate following local clustering at the 
kinetochore8,28,30.  This  may  explain  why  Mps1  activity  is  merely 
delayed  by  Aurora  B  inhibition,  because  reducing  kinetochore 
binding would be expected to only delay Mps1 activation. Delays 
in Mps1 activation can be assessed directly by immunoblotting to 
observe  the  hyperphosphorylated  state8,25,28  if  Mps1  activation  is 
synchronously induced. Aurora B inhibition delayed Mps1 hyper-
phosphorylation in a synchronized Mps1 re-activation assay (see 
below). Taken together, these data indicate that Aurora B inhibi-
tion substantially delays Mps1 activation, but does not altogether 
prevent it.
Rapid Mps1 activation by Aurora B requires Hec1. We hypoth-
esized that Aurora B recruitment to the inner centromere during 
prophase was responsible for initiating Mps1 recruitment and acti-
vation at kinetochores. In strong support of this, artificial recruit-
ment  of  Aurora  B  to  centromeres  before  mitosis,  by  inducible 
expression of CENPB–INCENP–GFP (CB-INCENP)31, caused acti-
vation of Aurora B and relocalization of Mps1 to kinetochores of 
G2-phase cells (Supplementary Fig. S5). To gain more insight into ARTICLE     
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the mechanism by which Aurora B recruits Mps1 to kinetochores, 
we depleted Ndc80/Hec1 (hereafter referred to as Hec1). Hec1 rep-
resented an attractive candidate to mediate kinetochore binding of 
Mps1 because budding yeast Hec1 directly interacts with Mps1 (ref. 
32), and is also directly phosphorylated by Aurora B15,16. Hec1 deple-
tion completely prevented the Aurora B-mediated recruitment of 
Mps1 to kinetochores in G2 (Fig. 2a), inhibited Mps1 recruitment to 
the kinetochore throughout mitosis and substantially delayed Mps1 
activation  (as  measured  by  Mad2  recruitment  to  kinetochores;   
Fig. 2b,c). We thus hypothesize that Aurora B–Hec1–Mps1 signal in 
a linear pathway at the beginning of mitosis to allow Mps1 activa-
tion and subsequent Mad2 recruitment to kinetochores. These data 
agree with earlier findings that Hec1 depletions affect kinetochore 
binding of Mps1 and imply that the concomitant reduction in Mad2 
seen by others33–35 is due to a delay in Mps1 activation. Mps1 may 
bind Hec1 directly32 or, given that Hec1 depletion also affects the 
localization of many other kinetochore components, may interact 
with a Hec1-dependent kinetochore protein.
Checkpoint  establishment  requires  efficient  Mps1  activation. 
Initiation of cyclin B degradation in mitosis marks the release of 
the APC/C from inhibition by the mitotic checkpoint1,36. To investi-
gate if the delayed Mps1 activation observed upon Aurora B inhibi-
tion or Hec1 depletion affected mitotic checkpoint activity, cyclin   
B–mCherry fluorescence was monitored in real time. Cyclin B levels   
in nocodazole-treated control cells remained stable for 2 h follow-
ing nuclear envelope breakdown before slow slippage was initiated 
(see arrows; Fig. 3a,b)37, indicating potent APC/C inhibition by the 
mitotic checkpoint. Aurora B inhibition (Fig. 3a) or Hec1 depletion 
(Fig. 3b), however, caused rapid degradation of cyclin B as soon as 
cells entered mitosis. Importantly, cyclin B was subsequently stabi-
lized within 15 min (to a rate approaching that induced by mitotic 
slippage),  indicating  that  checkpoint  establishment  was  merely 
delayed (Fig. 3a,b). These data imply that checkpoint activation is 
delayed as a consequence of the delay in Mps1 activation. In sup-
port of this, restoring Mps1 activity at kinetochores by the expres-
sion of Mis12–Mps1∆200 (Fig. 1d, Supplementary Fig. S2) prevented 
the rapid drop in cyclin B levels following mitotic entry in Aurora 
B-inhibited or Hec1-depleted cells (Fig. 3c,d). The observation that 
checkpoint  establishment  is  delayed  rather  than  fully  inhibited 
upon addition of Aurora B inhibitors is unlikely to reflect incom-
plete Aurora B inhibition, because combining Aurora B siRNA with 
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Figure 1 | Aurora B inhibition delays Mps1 activation at kinetochores. (a) HeLa cells treated with nocodazole containing Dmso or Hesperadin (100 nm) 
for 2 h and stained with the indicated antibodies. (b) mean total kinetochore intensities ( ± s.d.) of mps1 (dark red bars) or mad2 (pink bars) relative 
to centromeres (ACA), treated as in (a) or with Zm447439 (2 µm). Data are from 20 cells from two experiments (Hesperadin treatment) or 40 cells 
from four experiments (Dmso and Zm447439 treatments). Ratios in early prometaphase are set to 1. (c) Example immunofluorescent images and 
quantification of kinetochore signal intensities of mps1-pT676 over centromeres (ACA) in HeLa cells treated with nocodazole and indicated siRnAs or 
drugs. (d) Example immunofluorescent images and quantification of kinetochore signal intensities of mad2 over centromeres (ACA) in u2os cells, non-
induced or induced to express LAP–mis12–mps1∆200, and treated with nocodazole and indicate drugs. For panels c and d, ratio in si-mock or Dmso-treated 
cells is set to 1 and mean data ( ± s.d.) are from 20 individual cells from two independent experiments. All images most closely resemble the mean values. 
All standard deviations represent the deviation in mean total kinetochore intensities between all individual cells analysed. scale bars are 5 µm. For all 
experiments cells were treated with thymidine for 24 h, released into media containing nocodazole and indicated drugs for 10 h before fixation. siRnAs in 
panel c were transfected 16 h before the thymidine arrest.ARTICLE
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ZM447439 did not further sensitize the checkpoint (Supplemen-
tary Fig. S6).
If  Aurora  B  inhibition  affects  checkpoint  establishment  by 
decreasing the efficiency of Mps1 activation at the kinetochore, par-
tial Mps1 inhibition may cause similar delays in checkpoint estab-
lishment. Suboptimal doses (≤500 nM) of the Mps1 inhibitor revers-
ine25 caused inefficient Mps1 activation (as measured by delayed 
Mad2 kinetochore binding) and faster mitotic exit (Supplementary 
Figs S7 and S8a). Strikingly, increasing concentrations of reversine 
(62–500 nM) caused increasing delays in checkpoint establishment, 
as measured by Cyclin B stabilization in nocodazole (Fig. 3e).
Aurora B synergises with Hec1 and Mps1. Although potent Mps1 
inhibition and penetrant Hec1 depletion abrogate mitotic check-
point  activity8–10,25,27,35,  potent  Aurora  B  inhibition  does  not.  We 
hypothesized that if Aurora B and Hec1 are important for Mps1 to 
initiate checkpoint signalling, the checkpoint might be sensitized to 
Aurora B inhibition when downstream components of the pathway 
are functionally compromised. Indeed, inhibition or knockdown of 
any two individual components was functionally synergistic against 
the mitotic checkpoint response to nocodazole, as judged by meas-
uring the cumulative frequency of cells that exited mitosis at defined 
times after nuclear envelope breakdown (Fig. 4a–c). For instance, 
although  a  low  dose  of  reversine  (125 nM)  or  2 µM  ZM447439 
alone allowed cells to arrest in nocodazole for many hours, combin-
ing both compounds caused exit within 30 min (Fig. 4a). Given that 
potent Mps1 inhibition achieved similar fast exit (see Supplementary   
Fig. S8a,b), this is likely to reflect complete inactivation of the mitotic 
checkpoint. The synergy between Aurora B and partial Mps1 inhi-
bition occurred over a range of reversine doses (Supplementary   
Fig. S8a), and was further confirmed with an independent Mps1 
inhibitor, Mps1-IN-1 (Supplementary Fig. S8b)9, as well as with 
siRNA-mediated depletion of Mps1 and Aurora B (Supplementary 
Figs S6 and S8c). Furthermore, using a high dose of nocodazole 
(3.2 µM, see ref. 13) showed that this effect of Aurora B inhibition 
was not due to possible effects of Aurora B on residual microtubules 
(Supplementary Fig. S8d,e).
In line with the fact that Aurora B inhibition or partial Mps1 
inhibition only delayed establishment of the checkpoint (Fig. 3), 
combining Aurora B inhibitor with a very low dose of reversine 
(32.5 nM) resulted in a significantly longer delay, as measured by 
cyclin B fluorescence (Fig. 4d). Strikingly, the few cells that did not 
rapidly exit mitosis when treated with Hec1 siRNA combined with 
either a higher dose of reversine (250 nM) or Aurora B inhibitor (see 
Fig. 4b,c) had degraded cyclin B almost completely before check-
point signalling was capable of stabilizing it (Fig. 4e,f).
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Figure 2 | Hec1 depletion inhibits Mps1 recruitment and delays activation at kinetochores. (a) mean total kinetochore intensities ( ± s.d.) of mps1 (dark 
red bars), Hec1 (pink bars) or CB-InCEnP (orange bars) relative to centromeres (ACA) in G2-phase u2os cells (interphase cells 12 h after thymidine 
release into nocodazole) non-induced or induced to express CB-InCEnP (20 cells, two independent experiments). Ratios in si-mock treatments are set to 
1 for non-induced (mps1 and Hec1) or induced (CB-InCEnP) cells. The kinetochore signal for mps1 seen following si-Hec1 in non-induced controls reflects 
background staining as it is not reduced by si-mps1 (results not shown). (b) HeLa cells treated with mock or Hec1 siRnA and nocodazole before fixation 
and immunostaining with indicated antibodies. (c) mean total kinetochore intensities ( ± s.d.) of mps1 (dark red bars), mad2 (pink bars) or Hec1 (orange 
bars) relative to centromeres (ACA) from 20 cells from two independent experiments, treated as in b. Ratios in early prometaphase si-mock treatments 
are set to 1. All images most closely resemble the mean values. All standard deviations represent the deviation in mean total kinetochore intensities 
between all individual cells analysed. scale bars are 5 µm. For all experiments cells were transfected with siRnA for 16 h, thymidine added for a further 
24 h, before release into media containing nocodazole ( − / +  doxycycline in (a)) for 10 h before fixation.ARTICLE     
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The fast mitotic exit in nocodazole induced by Hec1 depletion 
combined with ZM447439 or Hesperadin treatment was prevented 
by  Mis12–Mps1∆200  expression  (Fig.  4g).  Moreover,  induction  of 
Mis12–Mps1∆200 also completely prevented any drop in cyclin B lev-
els upon mitotic entry, indicating that the checkpoint was still initi-
ated maximally as soon as cells enter mitosis if Mps1 was preserved 
at kinetochores (Fig. 4h). These data demonstrate that the synergy 
between  Aurora  B  inhibition  and  Hec1  depletion,  also  shown 
recently by others38, prevents mitotic checkpoint signalling because 
it causes long delays in Mps1 activation and checkpoint establish-
ment. In the majority of cells, the delay is long enough to prevent 
checkpoint activation before cyclin B degradation is complete and 
mitotic exit is initiated. Furthermore, the recruitment of Mps1 to 
kinetochores is the primary role for Aurora B and Hec1 in mitotic 
checkpoint signalling, because recovering Mps1 activity at kineto-
chores bypasses all checkpoint phenotypes associated with Aurora 
B inhibition and/or Hec1 depletion.
Aurora B is not critical to maintain Mps1 activity. Our data sup-
port the hypothesis that Aurora B co-operates with Hec1 to allow 
efficient Mps1 activation and checkpoint establishment at the begin-
ning of mitosis. Hec1 depletion sensitized the checkpoint to Aurora 
B inhibition (Fig. 4c); however, we observed no additional sensitiza-
tion when combining Aurora B inhibitors with Aurora B siRNAs 
(Supplementary Fig. S6). Therefore, we predict that Aurora B is an 
amplifier rather than an essential component required for Mps1 
activation at kinetochores. This amplifier allows rapid checkpoint 
establishment at mitotic onset, but is less important thereafter (at 
least in the continued presence of nocodazole; Fig. 3a). To address 
whether Aurora B was required at all to maintain the checkpoint 
after Mps1 activation is achieved, cyclin B levels were monitored 
in nocodazole-treated cells that received Aurora B inhibitor after 
mitotic entry. As shown in Figure 5a, ZM447439 addition caused 
a slight weakening of the checkpoint when given to cells already 
arrested  in  nocodazole.  This  moderate  effect  was  prevented  by 
expression  of  Mis12–Mps1∆200  (Fig.  5a),  showing  that  Aurora  B 
still impacted to some extent the ability of Mps1 to maintain the 
checkpoint during mitosis. Interestingly, Mps1 autophosphoryla-
tion sites that are required for its activity28,30 displayed slow turn-
over, as inhibiting Mps1 kinase activity during mitosis with 1 µM 
reversine was unable to cause dephosphorylation of Mps1 (pT676 
and mobility shift; Supplementary Fig. S9). In contrast, mitotic exit 
(lane 6 of Supplementary Fig. S9) or cdk1 inhibition (lane 3 of Sup-
plementary Fig. S9) efficiently dephosphorylated and thus inacti-
vated Mps1. This suggests that once activated, Mps1 no longer relies 
on activating inputs to be maintained in its active, hyperphospho-
rylated state during mitosis, possibly explaining the limited effect 
of Aurora B inhibition on the checkpoint when applied during a 
nocodazole arrest. To test this, we returned Mps1 to its hypophos-
phorylated, inactive state by inhibition of cdk1 and asked whether 
it could re-activate in mitosis in the absence of Aurora B activity. 
Nocodazole-arrested  cells  were  treated  with  the  cdk1  inhibitor 
RO3306 (combined with MG132 to prevent cyclin B degradation), 
which  caused  rapid  dephosphorylation  of  Mps1  within  20 min   
(Fig. 5b, Supplementary Fig. S9). Treatment was limited to 20 min to 
prevent mitotic exit (all chromosomes remained visibly condensed)39. 
Although  release  from  RO3306/MG132  quickly  re-established   
Mps1 activity as well as mitotic checkpoint function, both were 
severely delayed when cells were released from cdk1 inhibition in 
the presence of Aurora B inhibitors (Fig. 5b,c). This dependence on 
Aurora B was not observed if recovery from cdk1 inhibition was 
performed in cells induced to express Mis12–Mps1∆200 (Fig. 5d).
Discussion
These data demonstrate that Aurora B works together with Hec1 (or 
a Hec1-dependent kinetochore protein) to recruit Mps1 to kineto-
chores during mitosis. This pathway is essential to rapidly activate 
Mps1 at the onset of mitosis and thus ensure the checkpoint is effi-
ciently engaged.
A critical role for Aurora B in mounting a checkpoint response 
to unattached kinetochores has not previously been shown in mam-
malian cells, largely due to the fact that potent Aurora B inhibitors 
have been ineffective at preventing a nocodazole-induced mitotic 
delay13,22,23. Some studies, however, reported that such delays are 
significantly less pronounced when Aurora B is inhibited22,23. Our 
data explain why Aurora B inhibitors are ineffective in nocodazole-
treated cells and why these cells nevertheless exit faster than control 
cells. We propose that establishment of the checkpoint is merely 
delayed when Aurora B is inhibited, which is a direct result of a delay 
in Mps1 activation. When the checkpoint is eventually established, 
cells proceed with reduced cyclin B levels and slippage subsequently 
steadily reduces the remaining cyclin B (at a slightly accelerated 
rate) until cells eventually exit mitosis after several hours. There-
fore Aurora B inhibitors are effective at overriding the checkpoint 
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Figure 3 | Timely establishment of the mitotic checkpoint requires 
efficient Mps1 activation. Time-lapse imaging of cyclin B–mCherry 
fluorescence in mitotic u2os cells treated with nocodazole and (a) 
indicated inhibitors or (b) siRnA against Hec1. Time-lapse imaging of u2os 
cells non-induced or induced to express LAP–mis12–mps1∆200 and treated 
with (c) Zm447439 or (d) Hec1 siRnA. (e) Time-lapse imaging of cyclin 
B–mCherry fluorescence in mitotic u2os cells treated with nocodazole 
and indicated concentrations of reversine. Arrows in a, b indicate start of 
mitotic slippage. Fluorescence at nuclear envelope breakdown (nEB) was 
set to 100%. Data represent the mean ( ± s.d.) of at least 6–10 cells, which 
is representative of at least three independent experiments. All drugs 
were added before mitotic entry. For all siRnA experiments cells were 
transfected for 16 h, thymidine added for a further 24 h, and cells released 
into media containing nocodazole ( − / +  doxycycline in (d)).ARTICLE
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in nocodazole, but primarily during the very early stages of mito-
sis. Interestingly, a recent study showed both Aurora B and Mps1 
were required to propagate a mitotic checkpoint response on fully 
bioriented chromosomes when Mad1 was constitutively tethered 
to kinetochores40. It will be interesting to examine whether, under 
these conditions, Mps1 activity also relies on Aurora B-dependent 
recruitment to kinetochores.
Why then does Aurora B activity cease being critical to main-
tain a checkpoint when Mps1 activity has been established? Our 
data indicate that Aurora B merely amplifies Mps1 recruitment to 
kinetochores, which is important upon mitotic entry when Mps1 
must auto-activate efficiently to ensure that the mitotic checkpoint 
is engaged on time. Following this initial activation, however, the 
requirements for Aurora B may be relaxed while all kinetochores 
are able to functionally recruit active Mps1 and thereby propagate 
the checkpoint. However, this may only be a temporary reprieve, 
because as chromosomes congress the checkpoint would need to 
be maintained with progressively fewer unattached kinetochores. 
Although technically challenging, it will be important to address 
whether the checkpoint is more sensitive to Aurora B inhibitors in 
cells containing only few unattached kinetochores.
Hec1 is likely to be essential for Mps1 localization at kineto-
chores, given that Hec1 depletion combined with Aurora B inhi-
bition is very effective at overriding the checkpoint in nocodazole 
and yet this is still completely prevented by recovering Mps1 at 
kinetochores. This would explain the complete checkpoint override   
following  efficient  Hec1  depletion  seen  by  others35,  although  it 
remains to be formally tested whether recovering Mps1 recruit-
ment  would  similarly  recover  the  checkpoint  response  under 
these conditions. Ultimately, it will be critical to address whether 
Mps1 binds directly to Hec1 and, if so, how Aurora B-mediated 
phosphorylation(s) impacts on this association. A likely hypothesis, 
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Figure 4 | Aurora B, Hec1 and Mps1 synergize to establish the mitotic checkpoint. (a–c) Time-lapse analysis of duration of mitotic arrest in HeLa cells 
treated with nocodazole after combinations of siRnA and/or inhibitors, as indicated. Data indicate cumulative percentage of cells (from 50 cells per 
treatment) that exit mitosis (scored as cell flattening) at the indicated times after nEB, and are representative of 2–5 independent experiments. (d–f) 
Cyclin B–mCherry fluorescence of u2os cells treated with nocodazole in combination of siRnA and/or inhibitors, as indicated. In d, 32.5 nm reversine was 
used to observe the long mitotic delay, as this prevented fast mitotic exit in all cells following Zm447439 addition. In e and f, means for si-Hec  +  inhibitors 
were calculated from cells that did not exit mitosis within 2 h. (g) Time-lapse analysis of duration of mitotic arrest in u2os cells treated with Hec1 siRnA 
and indicated inhibitors in cells non-induced or induced to express LAP–mis12–mps1∆200. Data indicate cumulative percentage of cells (from 50 cells per 
treatment) that exit mitosis (scored as cell flattening) at the indicated times after nEB, and are representative of three independent experiments. (h) 
Cyclin B–mCherry fluorescence of u2os cells treated with Hec1 siRnA and Zm447439 and non-induced or induced to express LAP–mis12–mps1∆200. Data 
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based on our data and the direct biochemical interaction between 
the Hec1 N terminus and Mps1 in budding yeast32, is that Aurora B-
mediated phosphorylation of the Hec1 N-terminal tail potentiates 
direct interaction with Mps1.
Finally, we have previously shown that Mps1 enhances activa-
tion of Aurora B41, and that this is most apparent when cells enter 
mitosis with reduced Mps1 activity10. This suggests the possibility 
that Mps1 and Aurora B are engaged in a positive feedback loop 
that ensures rapid establishment of both the mitotic checkpoint and 
error-correction pathways at the beginning of mitosis. Experiments 
are underway to test this hypothesis.
Methods
Cell culture and reagents. HeLa cells were grown in DMEM supplemented 
with 8% fetal bovine serum, penicillin/streptomycin and l-glutamine (2 mM). 
All doxycycline-inducible cells lines were derived from U2OS-TR (a gift from M. 
Timmers) cultured in the same media but containing 8% Tet-approved fetal bovine 
serum (Clontech), and protein expression was induced by doxycycline addition 
(at 1 µg ml − 1) for at least 6 h. Thymidine (2.5 mM), nocodazole (830 nM), taxol 
(1 µM), MG132 (5 µM), reversine (various doses), doxycycline, G-418 (1 mg ml − 1) 
and puromycin (1 µg ml − 1) were all from Sigma. Zeocin (100 µg ml − 1) was from 
Invitrogen. RO3306 (Enzo Life Sciences) was used at 10 µM, ZM447449 (Tocris 
Bioscience) at 2 µM, Hesperadin (Selleck Chemicals) at 100 nM and Mps1-IN-1 
(gift from Nathanael Gray) at 10 µM throughout, unless stated otherwise.
Cell lines. The U2OS-TR cell line was transfected with pcDNA4 vector (Invitrogen) 
encoding LAP–Mis12–Mps1∆200, LAP–Mps1∆200 or CB-INCENP–GFP and selected 
with Zeocin. Monoclonal cells lines were then established by limited dilution (Clone 
9B; LAP–Mis12–Mps1∆200, Clone 23; LAP–Mps1∆200, Clone 6 CB-INCENP–GFP).  
Stable lines coexpressing cyclin B–mCherry were subsequently created by transfec-
tion of cyclin B–mCherry (based on a pEGP-N1 vector backbone; kind gift from  
R. Wolthuis) and selection with G-418. An inducible cyclin B U2OS-TR clone  
(Clone 3) was obtained by co-transfecting pcDNA5 encoding cyclin B–mCherry 
with pBabe-puro (10:1 ratio), selecting with puromycin and single cell cloning.
Antibodies. The following primary antibodies were used for immunofluorescence 
imaging and immunoblotting (at indicated final concentrations): Mps1-NT (Up-
state; 0.5 µg ml − 1), pT676-Mps128 (1 µg ml − 1), Mad2 (ref. 10; 0.5 µg ml − 1), α-tubulin 
(Sigma; 0.2 µg ml − 1), CREST/ACA (Fitzgerald Industry Int; 0.5 µg ml − 1), Aurora B 
(AIM, BD transduction; 0.25 µg ml − 1), pT232-Aurora B (Rockland; 0.5 µg ml − 1), 
Hec1 (9G3, Abcam; 1 µg ml − 1), cyclin B (H-433, Santa Cruz; 0.2 µg ml − 1). Second-
ary antibodies were high-crossed absorbed goat-anti-human Alexafluor647, 
goat-anti-rabbit and anti-mouse Alexafluor488 and Alexafluor568 (Molecular 
Probes) for immunofluorescence studies, and anti-Mouse/Rabbit-HRP (Bio-Rad) 
for immunoblotting.
Plasmids and siRNAs. LAP–Mis12–Mps1, LAP–Mps1 and CB-INCENP–GFP 
have been described24,31,41,42. LAP–Mis12–Mps1∆200 or LAP–Mps1∆200 were construct-
ed using Quickchange mutagenesis to create a Xho1 site at 600 bp, which was used 
to excise the first 600 bases of Mps1 from either LAP–Mis12–Mps1 or LAP–Mps1. 
Plasmids were transfected using Fugene 6 (Roche) according to the manufactur-
er’s instructions. siRNAs used in this study were as follows: si-Hec1 (5′-AAGU 
UCAAAAGCUGGAUGAUC-3′, custom; Dharmacon), si-Mps1 (5′-GACAGAU 
GAUUCAGUUGUA-3′, custom; Dharmacon), si-Mock (Luciferase GL2 duplex; 
Dharmacon/D-001100-01-20) and si-AurB (ON-TARGETplus si-RNA J-003326-
23, AURBKB, Dharmacon). All siRNAs were transfected using Hiperfect (Qiagen) 
at 20 nM according to the manufacturer’s instructions.
Live cell imaging and immunfluorescence. For live cell imaging, cells were plated 
in four-well or eight-well chambered glass-bottom slides (LabTekII) or 24-well 
glass-bottom plates (MatTek), transfected and imaged in a heated chamber (37°C 
and 5% CO2) using a ×10/0.3NA CPlanFLN or ×20/0.5NA UPLFLN objective  
on a Olympus IX-81 microscope, controlled by Cell-M software (Olympus).  
Images were acquired using a Hamamatsu ORCA-ER camera and processed  
using Cell-M software.
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For immunofluorescence studies, cells plated on 12-mm coverslips, were 
pre-extracted with 0.2% Triton X-100 in PEM (100 mM PIPES (pH 6.8), 1 mM 
MgCl2 and 5 mM EGTA) for 45 s before fixation with 4% paraformaldehyde in 
PBS (for Mps1, Mad2 and Hec1). Aurora B and pAurB stainings were performed 
on cells fixed directly in 4% paraformaldehyde. Coverslips were blocked with 2% 
bovine serum albumin in PBS/0.1% Triton for 15 min, incubated with primary 
antibody for 16 h at 4 °C, washed with PBS, and incubated with secondary antibod-
ies and 4,6-diamidino-2-phenylindole for an additional 2 h at room temperature. 
Coverslips were washed and mounted using ProLong antifade (Molecular Probes). 
All images were acquired on a DeltaVision RT system (Applied Precision) with a 
×100/1.40NA UPlanSApo objective (Olympus) using SoftWorx software. Images 
are maximum intensity projections of deconvolved stacks.
For quantification of immunostaining, all images of similarly stained experi-
ments were acquired with identical illumination settings and analysed using 
ImageJ. An ImageJ macro was designed to threshold and select all centromeres 
and all chromosomes areas (excluding centromeres), using the 4,6-diamidino-
2-phenylindole and ACA channels. The convolve filter was first applied to the 
ACA channel and the threshold selection increased by 1 pixel (to ensure complete 
kinetochore selection). This was used to calculate the relative mean kinetochore 
intensity of Mad2, Mps1 and Hec1 ([centromere–chromosome arm intensity 
(Mad2/Mps1/Hec1)]/[centromere–chromosome arm intensity (ACA)]). For cen-
tromere localization of AurB/pAurB, a true background outside the cell was used 
to subtract from the centromere intensity (and centromere areas were enlarged by 
3 pixels to incorporate the more diffuse Aurora B staining).
For quantification of cyclin B–mCherry fluorescence, ImageJ was used to 
calculate the total integrated fluorescence intensity of individual cells at each time 
point (after background subtraction of all images using a rolling ball radius of 200 
pixels).
For all kinetochore intensity quantifications, means and standard deviations 
were calculated for each individual experiment and then combined using the 
standard method for non-overlapping data sets. 
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